ThursdayJun 04, 2026 10:00 am

Pediatric Brain Tumors Spread Faster as Immune Cells Build Enabling Scaffolding

Scientists have identified a potential mechanism through which aggressive pediatric brain tumors called diffuse midline gliomas spread. The researchers found that immune cells within the brain, called microglia, produce proteins called fibronectin that help the tumors to progress.  The findings, published in the Cell Death & Disease journal, offer a possible mechanism that can be targeted in efforts to develop effective treatments against these tumors.  Conducted by a team at Karolinska Institutet, the researchers aimed to investigate what role microglia played in tumor progression and how these cells are impacted by the cancer. In their study, the team found that when microglia are exposed to diffuse midline glioma (DMG) cells, they respond by producing large quantities of fibronectin and…

Continue Reading

ThursdayJun 04, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?

Humanitas collaboration supports Regentis’ physician adoption strategy and broader commercial infrastructure across the European market. GelrinC targets a large orthopedic market that currently lacks an approved off-the-shelf regenerative cartilage repair solution. Pivotal FDA enrollment, manufacturing scale-up, physician engagement initiatives and CE Mark status position the company toward multiple potential value-inflection milestones. Regenerative medicine has long promised to transform patient care, but investors often become most interested when innovative science begins transitioning toward commercial adoption. Regentis Biomaterials (NYSE American: RGNT) is approaching that transition with GelrinC(R), its cartilage regeneration platform targeting a large orthopedic market where treatment alternatives continue to involve meaningful trade-offs. The…

Continue Reading

WednesdayJun 03, 2026 9:45 am

Earth Science Tech Inc. (ETST) Pairs Healthcare Expansion with Aggressive Share Repurchases

Earth Science Tech has evolved into a diversified healthcare holding company with operations spanning telemedicine, compounding pharmacies, clinical support services and healthcare fulfillment. In addition, the company has actively reduced its share count through a series of share repurchases documented in SEC filings and share structure records. Earth Science Tech repurchased 3.7 million shares over the nine months ended December 31, 2025, spending approximately $647,000. Management continues to emphasize shareholder value through balance-sheet management alongside acquisitions and operating growth. The company is scheduled to present to investors at the Planet MicroCap Las Vegas 2026 conference in June. For many investors…

Continue Reading

WednesdayJun 03, 2026 9:00 am

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as key…

Continue Reading

WednesdayJun 03, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level. Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for an unmet need in multiple sclerosis. The company has also expanded its presence in a consumer ready product in the field of alcohol health and sobriety through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to…

Continue Reading

TuesdayJun 02, 2026 10:00 am

New Inhalable Agent Could Improve Treatment Outcomes in Lung Cancer

A new viral-based vector that can be inhaled into the lungs could boost the anti-cancer response of the body in patients diagnosed with advanced lung cancer. This new treatment could also restore sensitivity to immune checkpoint inhibitors among patients that had become unresponsive.  The new investigational therapy, dubbed KB707, was developed by a team at Cleveland Clinic Cancer Institute. The treatment is based on a vector platform leveraging a modified herpes simplex virus that is non-replicating. The agent delivers cytokines IL-12 and IL-2 directly into the lungs once the patient inhales it.  This delivery via inhalation helps to get the therapy into the microenvironment of the tumors in the lungs, and the…

Continue Reading

MondayJun 01, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Holds $388M JV Valuation as Pipeline Momentum Builds

Oncotelic Therapeutics maintained the fair value of its 45% GMP Biotechnology JV stake at approximately $388 million in Q1 2026 despite broader biotech market volatility The valuation was supported by an independent ASC 820 Level 3 assessment using discounted cash flow analysis and market comparables These developments reinforce Oncotelic’s partnership-driven model, designed to advance a multi-billion-dollar oncology pipeline while limiting traditional biotech cash burn pressures Oncotelic Therapeutics (OTCQB: OTLC) continues to distinguish itself within a biotechnology sector often characterized by aggressive capital raises and persistent cash burn. In its recently filed first-quarter 2026 financial results, the company maintained the fair value…

Continue Reading

MondayJun 01, 2026 9:00 am

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled…

Continue Reading

FridayMay 29, 2026 10:00 am

US CDC Broadens Ebola Travel Ban to Include Green Card Holders

The Centers for Disease Control and Prevention (CDC) in the U.S. has extended the recently issued travel ban on individuals who have been to Uganda, South Sudan, and the Democratic Republic of Congo (DRC) during the past 21 days to now include green card holders. The reason given for this broadened ban is to prevent the disease from being brought into the country by legal permanent residents.  The previous travel ban had excluded U.S. citizens, green card holders and other nationals and was to be in effect for 30 days. However, the CDC issued a notice including green card holders in that travel ban. Only…

Continue Reading

ThursdayMay 28, 2026 10:00 am

Climate Change Amplifies Infectious Disease Risks, Experts Warn

According to advice published in the Netherlands last week, climate change is increasing the risk of not just infectious diseases but also cancer and heat stress. This concern has implications not just in the U.S. but globally as well.  In their advisory that was issued on Thursday, the Scientific Climate Council and the Dutch Health Council caution that health impacts connected to climate change are increasing at a rate that hadn’t been previously expected.  The two councils urge for additional protection for all people. They say if these extra protective measures aren’t speedily implemented, heat-linked fatalities due to climate change could multiply six-fold by 2050 in the Netherlands. The Netherlands isn’t the only country facing climate change, so…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000